European genetics study of hearing impairment in patients with cancer during childhood treated with cisplatin.

European genetics study of hearing impairment in patients with cancer during childhood treated with cisplatin. - Genetic variation in ototoxicity after cisplatin treatment in children.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41760

Enrollment

100

Registered

2015-02-19

Start date

2015-04-20

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hearing impairment ototoxicity

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treated with cisplatin Diagnosed before the age of 18 years End-of treatment pure tone audiograms No radiotherapy administered to head/neck Normal pre-treatment audiogram

Exclusion criteria

Exclusion criteria: No informed consent Pre-existing known hearing impairment

Design outcomes

Primary

Measure	Time frame
Difference in genetic profile between patients with and without ototoxicity. Audiograms.	—

Secondary

Measure	Time frame
Age. Treatment regimen. Co-treatment with diuretics and aminoglycosides. Renal function.	—

Countries

Netherlands

Outcome results